Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy

Prostate

Volumn 67, Issue 4, 2007, Pages 447-455

  Mikkola, Arto ^a   Aro, Jussi ^a   Rannikko, Sakari ^a   Ruutu, Mirja ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Androgen deprivation; Complication; Estrogen; Parenteral; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; POLYESTRADIOL PHOSPHATE; TESTOSTERONE; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BRAIN INFARCTION; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; ESTRADIOL BLOOD LEVEL; HEART INFARCTION; HOT FLUSH; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; ORCHIECTOMY; OSTEOPOROSIS; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGENS; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33847376805     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20547     Document Type: Article

References (51)

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2. Byar DP, Corle DK. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-170.
3. Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995;28:273-283.
4. Jonsson G. Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol. Scand J Urol Nephrol 1971;5:97-102.
5. Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Hansson E, Juusela H, Permi J, Saarialho M, Viitanen J, Alfthan O. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Br J Urol 1991;67:184-187.
6. Haapiainen R, Rannikko S, Alfthan O. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective cancer study. Br J Urol 1986;58:528-533.
7. Norlen BJ, Fritjofsson A, Gronquist L, Gunnarsson PO, Johansson SA. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer. Eur Urol 1987;13:193-197.
8. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, von Schoultz B. Single-drug parenteral estrogen treatment in prostatic cancer: A study of two maintenance-dose regimens. Prostate 1989;14:183-188.
9. Haapiainen R, Rannikko S, Alfthan O. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group. Br J Urol 1990;66:94-97.
10. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E, Scandinavian Prostatic Cancer Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer-Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36:405-413.
11. Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M. Finnprostate group. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 2005;39:249-300.
12. Mostofi FK. International histological classification of tumours, No. 22. Histological typing of prostate tumours. Geneva, Switzerland: WHO; 1980.
13. TNM: Classification of malignant tumours, Harmer MH, editor. 3rd edition. Geneva, Switzerland: International Union Against Cancer, 1982. pp 118-121.
14. Weimar C, Kraywinkel K, Rodl J, Hippe A, Harms L, Kloth A, Diener HC. German Stroke Data Bank Collaborators. Etiology, duration, and prognosis of transient ischemic attacks: An analysis from the German Stroke Data Bank. Arch Neurol 2002;59:1584-1588.
15. Donnelly R, Yeung JM. Management of intermittent claudication: The importance of secondary prevention. Eur J Vasc Endovasc Surg 2002;23:100-107.
16. Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial infarction, and vascular death in "low risk" patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 2003;74:577-580.
17. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, Taubert KA. American Heart Association/American Stroke Association. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: A scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003;34:2310-2322.
18. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-49.
19. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-2745.
20. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: Scientific review. JAMA 2002;288:1388-1395.
21. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, Romas E, Clemens L, Dragicevic G, Harianto H, Wicks I, McColl G, Best J, Jenkins A. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:81-89.
22. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
23. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
24. Gibbons RJ, Smith S, Antman E. American College of Cardiology. American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines: Part I: Where do they come from? Circulation 2003;107:2979-2986.
25. Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 2006;61:730-737.
26. Alfthan O, Holsti LR. Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma. Scand J Urol Nephrol 1969;3:183-187.
27. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: A controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002;13:1-5.
28. Hienert G, Kirchheimer JC, Pfluger H, Binder BR. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 1988;140:1466-1469.
29. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999;39:123-129.
30. Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R, von Schoultz B. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate 1989;14:177-182.
31. Henriksson P, Blomback M, Bratt G, Edhag O, Eriksson A, Vesterqvist O. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989;6:219-225.
32. Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol 1990;17:161-165.
33. Henriksson P, Blomback M, Eriksson A, Stege R, Carlstrom K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br Med J 1990;65:282-285.
34. Ockrim JL, Lalani el-N, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005;174:527-533.
35. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRh analogs. J Clin Endocrinol Metab 2002;87:3656-3661.
36. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-186.
37. Bruder JM, Ma JZ, Basler JW, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006;67:152-155.
38. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
39. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007.
40. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274.
41. Mikkola AK, Aro JL, Rannikko SA, Salo JO. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group. Prostate 1999;39:175-181.
42. Carlstrom K, Stege R, Henriksson P, Grande M, Gunnarsson PO, Pousette A. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate 1997;31:193-197.
43. Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, Laniado ME, Carter SS, Abel PD. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004;172:2203-2207.
44. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994;152:1170-1173.
45. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000;55:97-101.
46. Spetz AC, Hammar M, Lindberg B, Spangberg A, Varenhorst E. Scandinavian Prostatic Cancer Group-5 Trial study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001;166:517-520.
47. Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: The rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003;170:1703-1708.
48. Kloz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161:169-172.
49. Burns-Cox N, Basketter V, Higgins B, Holmes S. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int J Urol 2002;9:431-434.
50. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 2000;85:1069-1073.
51. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estradiol therapy for advanced prostate cancer-forward to the past? J Urol 2003;169:1735-1737.